Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Keros Therapeutics, Inc. (KROS) had Return on Equity of -8.30% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.37M |
|
$-23.71M |
|
-- |
|
$0.37M |
|
$26.24M |
|
$-25.88M |
|
$2.17M |
|
$-23.71M |
|
$-23.71M |
|
$-23.71M |
|
$-23.71M |
|
$-23.71M |
|
$-23.71M |
|
$-25.88M |
|
$-25.47M |
|
19.63M |
|
19.63M |
|
$-1.21 |
|
$-1.21 |
|
| Balance Sheet Financials | |
$290.68M |
|
$3.96M |
|
$21.62M |
|
$312.29M |
|
$12.85M |
|
-- |
|
$13.81M |
|
$26.66M |
|
$285.63M |
|
$285.63M |
|
$285.63M |
|
19.73M |
|
| Cash Flow Statement Financials | |
$-3.53M |
|
$-0.07M |
|
$-2.32M |
|
$288.86M |
|
$282.95M |
|
$-5.92M |
|
$6.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
22.62 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-7050.95% |
|
-7050.95% |
|
-- |
|
-6459.95% |
|
-6459.95% |
|
$-3.60M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.14 |
|
649.86 |
|
|
Return on Equity |
-8.30% |
-8.30% |
|
-7.59% |
|
-8.30% |
|
$14.47 |
|
$-0.18 |
|
$-0.18 |
|